S
S-H.I. Ou
Researcher at University of California, Irvine
Publications - 64
Citations - 2359
S-H.I. Ou is an academic researcher from University of California, Irvine. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Crizotinib. The author has an hindex of 16, co-authored 64 publications receiving 1279 citations.
Papers
More filters
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Tony Mok,D.R. Camidge,Shirish M. Gadgeel,Rafael Rosell,Rafal Dziadziuszko,Dai Woo Kim,Maurice Pérol,S-H.I. Ou,Joonghyun Ahn,Alice T. Shaw,Walter Bordogna,Vlatka Smoljanovic,Magalie Hilton,Thorsten Ruf,Johannes Noe,Solange Peters +15 more
TL;DR: The publisher regrets that this article has been temporarily removed and a replacement will appear as soon as possible in which the reason for the removal will be specified.
Journal ArticleDOI
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
Alexander Drilon,Alexander Drilon,G.G. Li,Snjezana Dogan,Mrinal M. Gounder,Mrinal M. Gounder,Ronglai Shen,Maria E. Arcila,Liang Wang,David M. Hyman,David M. Hyman,Jaclyn F. Hechtman,G. Wei,N. R. Cam,Jason Christiansen,D. Luo,Edna Chow Maneval,Todd M. Bauer,Manish R. Patel,Stephen V. Liu,S-H.I. Ou,Anna F. Farago,Alice T. Shaw,R. F. Shoemaker,J. Lim,Zachary Hornby,Pratik S. Multani,M. Ladanyi,M.F. Berger,Nora Katabi,Ronald Ghossein,Alan L. Ho,Alan L. Ho +32 more
TL;DR: A patient with an ETV6-NTRK3-driven mammary analogue secretory carcinoma to treatment with a pan-Trk inhibitor and the development of acquired resistance linked to a novel NTRK 3 mutation that interferes with drug binding is described.
Journal ArticleDOI
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Shirish M. Gadgeel,Solange Peters,Tony Mok,Alice T. Shaw,Dong Wan Kim,S-H.I. Ou,Maurice Pérol,Anna Wrona,Silvia Novello,Rafael Rosell,Ali Zeaiter,Ting Liu,Eveline Nüesch,Bogdana Balas,D.R. Camidge +14 more
TL;DR: Alectinib demonstrated superior CNS activity and significantly delayed CNS progression versus crizotinib in patients with previously untreated, advanced ALK+ NSCLC, irrespective of prior CNS disease or radiotherapy.
Journal ArticleDOI
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
Jessica J. Lin,Stephen V. Liu,Caroline E. McCoach,Viola W. Zhu,Aaron C. Tan,Satoshi Yoda,Jennifer L Peterson,Andrew Do,Kylie Prutisto-Chang,Ibiayi Dagogo-Jack,Lecia V. Sequist,Lori J. Wirth,Jochen K. Lennerz,Aaron N. Hata,Mari Mino-Kenudson,Valentina Nardi,S-H.I. Ou,Daniel Shao-Weng Tan,Justin F. Gainor +18 more
TL;DR: RET solvent front mutations are a recurrent mechanism of RET inhibitor resistance, although they occurred at a relatively low frequency, and next-generation RET inhibitors with potency against RET resistance mutations and combination strategies are needed to effectively overcome resistance in these patients.